论文部分内容阅读
目的:为观察门冬氨酸钾镁和胺碘酮治疗充血性心力衰竭合并室性心律失常的疗效及副作用发生情况。方法将我院2002年1月～2005年1月收治的充血性心力衰竭合并室性心律失常患者118例,随机分为两组:治疗组62例,常规治疗加门冬氨酸钾镁和胺碘酮;对照组56例,常规治疗加胺碘酮。共用4周。结果治疗组总有效率91.9%,QT离散度(QTd)由66.05±11.32ms减至30.28±6.25ms;对照组总有效率73.2%,QTd由65.38±11.46ms减至42.38±10.16ms。两组对比差异有显著性(P<0.05)。结论门冬氨酸钾镁和胺碘酮治疗充血性心力衰竭合并室性心律失常有较好疗效,且副作用较少发生。
Objective: To observe the curative effect and side effects of potassium-magnesium aspartate and amiodarone in patients with congestive heart failure complicated with ventricular arrhythmia. Methods A total of 118 patients with congestive heart failure and ventricular arrhythmia admitted to our hospital from January 2002 to January 2005 were randomly divided into two groups: treatment group (n = 62), conventional treatment with potassium magnesium and aspartate and amine 56 cases of control group, routine treatment plus amiodarone. Shared for 4 weeks. Results The total effective rate was 91.9% and the QTd was reduced from 66.05 ± 11.32ms to 30.28 ± 6.25ms in the treatment group. The total effective rate in the control group was 73.2%, and the QTd decreased from 65.38 ± 11.46ms to 42.38 ± 10.16ms. The difference between the two groups was significant (P <0.05). Conclusions Potassium and magnesium aspartate and amiodarone are effective in treating congestive heart failure with ventricular arrhythmia, with fewer side effects.